Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35

Summary

Ascletis announced the initiation of two Phase 1 studies in the U.S. for obesity treatments: ASC36, a once-monthly amylin receptor peptide agonist, and ASC36_35FDC, a potentially first-in-class fixed dose combination targeting amylin receptor, GLP-1R, and GIPR.